Found 30 results
Filters: keyword is Humans [Clear All Filters]
2006
.
2006. Two approaches to drug discovery in SOD1-mediated ALS.
J Biomol Screen. 11:729-35. Abstract
2005
.
2005. A high-throughput screen to identify inhibitors of amyloid beta-protein precursor processing.
J Biomol Screen. 10:1-12. Abstract
2004
.
2004. Development of an assay to screen for inhibitors of tau phosphorylation by cdk5.
J Biomol Screen. 9:122-31. Abstract
2003
.
2003. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line.
Chem Biol. 10:837-46. Abstract
2002
.
2002. Cripto-1 activates nodal- and ALK4-dependent and -independent signaling pathways in mammary epithelial Cells.
Mol Cell Biol. 22:2586-97. Abstract
.
2002. Discovery of compounds that will prevent tau pathology.
J Mol Neurosci. 19:261-6. Abstract
2001
.
2001. Enhanced potency of human Sonic hedgehog by hydrophobic modification.
Biochemistry. 40:4359-71. Abstract
.
2001. Fucosylation of Cripto is required for its ability to facilitate nodal signaling.
J Biol Chem. 276:37769-78. Abstract
.
2001. Homogeneous cell-based fluorescence polarization assay for the direct detection of cAMP.
J Biomol Screen. 6:75-82. Abstract
.
2001. N-terminal fatty-acylation of sonic hedgehog enhances the induction of rodent ventral forebrain neurons.
Development. 128:2351-63. Abstract
.
2001. Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation.
Nat Immunol. 2:172-80. Abstract
.
2001. Sonic hedgehog restricts adhesion and migration of neural crest cells independently of the Patched- Smoothened-Gli signaling pathway.
Proc Natl Acad Sci U S A. 98:12521-6. Abstract
2000
.
2000. Mapping sonic hedgehog-receptor interactions by steric interference.
J Biol Chem. 275:10995-1001. Abstract
.
2000. Regular articles: conditional disruption of hedgehog signaling pathway defines its critical role in hair development and regeneration.
J Invest Dermatol. 114:901-8. Abstract
.
2000. The EGF-CFC family: novel epidermal growth factor-related proteins in development and cancer.
7:199-226. Abstract
1999
.
1999. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin.
J Pharmacol Exp Ther. 290:635-40. Abstract
.
1999. Functional antagonists of sonic hedgehog reveal the importance of the N terminus for activity.
J Cell Sci. 112 ( Pt 2:4405-14. Abstract
.
1999. Zinc-dependent structural stability of human Sonic hedgehog.
Biochemistry. 38:14868-80. Abstract
1998
.
1998. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin.
J Pharmacol Exp Ther. 284:356-61. Abstract
.
1998. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians.
Pharmacogenetics. 8:129-35. Abstract
.
1998. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin.
J Pharmacol Exp Ther. 286:1490-5. Abstract
.
1998. Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen.
Arch Biochem Biophys. 357:240-8. Abstract
.
1998. Identification of a palmitic acid-modified form of human Sonic hedgehog.
J Biol Chem. 273:14037-45. Abstract
1996
.
1996. Affinity-based screening of combinatorial libraries using automated, serial-column chromatography.
Nat Biotechnol. 14:504-7. Abstract
.
1996. Identification of residues 99, 220, and 221 of human cytochrome P450 2C19 as key determinants of omeprazole activity.
J Biol Chem. 271:12496-501. Abstract